Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
NEW YORK, April 3, 2008 /PRNewswire/ -- QED International Associates Inc., administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM...
Possis Medical, Inc. (NASDAQ: POSS), a developer, manufacturer and marketer of pioneering medical devices used in endovascular procedures, today announced that the United States...
NEW YORK, March 17 /PRNewswire/ -- Standard & Poor's will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: -- MoneyGram International Inc. (NYSE:MGI) will be removed...
Possis Medical, Inc. (NASDAQ: POSS), a developer, manufacturer and marketer of pioneering medical devices used in endovascular procedures, today reported results for its fiscal...
Possis Medical, Inc. (NASDAQ: POSS), a developer, manufacturer and distributor of pioneering medical devices used in endovascular procedures, announced today that it will report...
Bayer HealthCare affiliate MEDRAD, Inc., Warrendale, PA and Possis Medical, Inc., Minneapolis, MN, (Nasdaq:POSS), announced today that they have entered into a definitive merger...
Possis Medical, Inc. (NASDAQ: POSS), a developer, manufacturer and distributor of pioneering medical devices used in endovascular procedures, today launched a new Web site to...
Possis Medical, Inc. (NASDAQ: POSS), today announced that it is participating in the Sidoti & Company, LLC, Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum...
NEW YORK, Oct. 18 /PRNewswire/ -- On October 2, Paul Lisenby, Chairman and CEO of XTend Medical Corp. (Pink Sheets: XMDC) updated the investment community in an all-new interview with...
Possis Medical, Inc. (NASDAQ:POSS), a developer, manufacturer and marketer of pioneering medical devices used in endovascular procedures, today reported preliminary sales for...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
